
MD, resident in urology @UKEHamburg | former research fellow @Uro_MedUniWien @MedUni_Wien | views are on my own
Hamburg, Vienna
Joined February 2022
- Tweets66
- Following216
- Followers137
- Likes185
Markus von Deimling retweeted
Thrilled to publish first results from a study that started almost 8 years ago: standardized morbidity & PROMs reporting after #RC. Short-term morbidity does not appear to impact 6-mo #HRQOL.
eu-openscience.europeanurolo…
@m_koelker @jakobfelin @mvdeimling @apachollek @fluebbersmeyer
Prospective evidence from the COMPACT registry: Limited impact of perioperative complications on 6mo HRQOL. Check out our latest publication @EurUrolOpen
doi.org/10.1016/j.euros.2025…
A big thank you to @mwvetterlein
Markus von Deimling retweeted
Prospective evidence from the COMPACT registry: Limited impact of perioperative complications on 6mo HRQOL. Check out our latest publication @EurUrolOpen
doi.org/10.1016/j.euros.2025…
A big thank you to @mwvetterlein
Markus von Deimling retweeted
Great talk by @TamsinGreenwel1 on a rare but important topic — female urethral reconstruction. World-class experts sharing their experience in live and semi-live surgeries at IMORU XI in #Hamburg. Congrats, Tamsin! #Urology #Urethroplasty #IMORUXI
Markus von Deimling retweeted
Replying to @JillC_Buckley
@JillC_Buckley sharing her roadmap for decision making around radiation-associated urethral stricture management - Very Useful! #IMORU25 – at Hamburg, Germany
Markus von Deimling retweeted
Welcoming the reconstructive urology community to Hamburg! Prof. Margit Fisch kicks off IMORU IX @UKEHamburg with live and semi-live surgeries on genitourinary complications. @JillC_Buckley presents a sophisticated algorithm for managing radiogenic strictures & stenoses. #IMORU – at Hamburg, Germany
Markus von Deimling retweeted
Looking forward to an intensive 3-day reconstructive urology deep-dive in Hamburg, March 26-28. Registration is still open! @IMORU
The @IMORU 2025 program is set! Join us at @UKEHamburg for 20 live & 14 semi-live surgeries, expert lectures & interactive discussions with 30+ top international reconstructive surgeons. Register now: imoru.de/registration #IMORU2025
Markus von Deimling retweeted
The @IMORU 2025 program is set! Join us at @UKEHamburg for 20 live & 14 semi-live surgeries, expert lectures & interactive discussions with 30+ top international reconstructive surgeons. Register now: imoru.de/registration #IMORU2025 – at Hamburg, Germany
Markus von Deimling retweeted
In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN
Markus von Deimling retweeted
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive #BladderCancer. #BeyondTheAbstract with @mvdeimling, and @DrShariat. #ReadNow on UroToday > bit.ly/4cgbGHU @BJUIjournal #CLIPOLY
Markus von Deimling retweeted
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive #BladderCancer. #BeyondTheAbstract with @mvdeimling, and @DrShariat. #ReadNow on UroToday > bit.ly/4cgbGHU @BJUIjournal #CLIPOLY
Markus von Deimling retweeted
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy
@gehi87 @E_Laukhtina @K_Tatsushi @DrShariat @schmidingerRCC
doi.org/10.1111/bju.16336
Markus von Deimling retweeted
In cN+ #BladderCancer treated with cisplatin-based induction CTX followed by RC we found no difference in #PathologicalResponse and OS/CSS between delivering three and four cycles - @mvdeimling @LAUrology_NL et al
doi.org/10.1111/bju.16319
We need procedure-specific comorbidity assessments, as standard comorbidity indices are too generic to predict postop. morbidity! Check out our latest paper authors.elsevier.com/a/1iOuo…
@mwvetterlein @DrShariat @MichaelRink_MD @JakobFelin @M_Koelker @VMS78880496 @FredKoenig @PAEGild
Check out our paper @BJUIjournal:
-> no oncologic benefit to extended PLND at RC in cN+ BCa regardless of periop chemo
~ 30% distant Mx
~ 13% locoregional rec
⛔️ cN+ is associated with a significant staging bias
Thanks to @BenjaminPradere and @DrShariat
doi.org/10.1111/bju.16210
Markus von Deimling retweeted
Online Now: Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive #BladderCancer by @mvdeimling et al.
doi.org/10.1111/bju.16210
Markus von Deimling retweeted
Carboplatin vs cisplatin-based chemotherapy for lymph node-positive #BladderCancer. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by von Deimling et al. in @EUplatinum > bit.ly/42AaVDL @mvdeimling @LAUrology_NL
Markus von Deimling retweeted
Carboplatin vs cisplatin-based chemotherapy for lymph node-positive #BladderCancer. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by von Deimling et al. in @EUplatinum > bit.ly/42AaVDL @mvdeimling @LAUrology_NL
Markus von Deimling retweeted
Neutrophil-to-lymphocyte ratio as a potential biomarker in patients with localized #UrothelialCarcinoma treated with chemotherapy. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work from von Deimling et al. on UroToday > bit.ly/3Lt3Sr7 @mvdeimling @DrShariat
Markus von Deimling retweeted
Novel systemic therapies are effective in men with mHSPC and mCRPC irrespective of visceral metastasis status
auajournals.org/doi/10.1097/…
























